- Home
- NRXS vs BRTX Comparison
NRXS vs BRTX Comparison
Compare NRXS & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- BRTX
- Stock Information
- Founded
- NRXS 2011
- BRTX 1997
- Country
- NRXS United States
- BRTX United States
- Employees
- NRXS N/A
- BRTX N/A
- Industry
- NRXS
- BRTX Managed Health Care
- Sector
- NRXS
- BRTX Health Care
- Exchange
- NRXS Nasdaq
- BRTX Nasdaq
- Market Cap
- NRXS 17.8M
- BRTX 15.9M
- IPO Year
- NRXS 2023
- BRTX N/A
- Fundamental
- Price
- NRXS $2.31
- BRTX $1.80
- Analyst Decision
- NRXS
- BRTX Strong Buy
- Analyst Count
- NRXS 0
- BRTX 1
- Target Price
- NRXS N/A
- BRTX $18.00
- AVG Volume (30 Days)
- NRXS 22.4K
- BRTX 812.7K
- Earning Date
- NRXS 04-08-2025
- BRTX 03-28-2025
- Dividend Yield
- NRXS N/A
- BRTX N/A
- EPS Growth
- NRXS N/A
- BRTX N/A
- EPS
- NRXS N/A
- BRTX N/A
- Revenue
- NRXS $2,456,219.00
- BRTX $377,000.00
- Revenue This Year
- NRXS $383.16
- BRTX $482.76
- Revenue Next Year
- NRXS N/A
- BRTX $212.24
- P/E Ratio
- NRXS N/A
- BRTX N/A
- Revenue Growth
- NRXS N/A
- BRTX 189.55
- 52 Week Low
- NRXS $2.05
- BRTX $1.03
- 52 Week High
- NRXS $3.78
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NRXS 38.24
- BRTX 37.55
- Support Level
- NRXS $2.39
- BRTX $2.26
- Resistance Level
- NRXS $2.51
- BRTX $2.38
- Average True Range (ATR)
- NRXS 0.15
- BRTX 0.22
- MACD
- NRXS -0.03
- BRTX -0.09
- Stochastic Oscillator
- NRXS 7.14
- BRTX 7.98
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.